Corrigendum to "Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product" [Obesity Pillars 12C (2024) 100138].

[This corrects the article DOI: 10.1016/j.obpill.

Taxonomy of the Rhampholeon boulengeri Complex (Sauria: Chamaeleonidae): Five New Species from Central Africa's Albertine Rift.

In a recent molecular study, the pygmy chameleon Rhampholeon boulengeri Steindachner, 1911 was shown to contain six genetically distinct, but phenotypically cryptic lineages. Phylogenetic analyses of genetic data demonstrated that several well-supported clades occurred in non-overlapping elevational ranges across the Albertine Rift in Central Africa. In order to resolve the taxonomy of the R.

Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product.

Background: The use of meal replacement products (MRPs) to obtain a caloric deficit while maintaining micro- and macronutrient requirements, has a long tradition in obesity medicine. Limitations include low compliance, variability in efficacy, adverse events (related to acute changes in nutrient intake), and risk of weight regain when discontinued, and their popularity has declined after the emergence of potent GLP-1 receptor analogues (GLP1-RAs). However, GLP-1RAs have limitations, including dose-dependent risk for adverse events (AEs), high cost, as well as weight regain when discontinued.

The future is bright: artificial intelligence for trainee medical officers in Australia and New Zealand.

Given their frontline role in Australia and Aotearoa New Zealand (ANZ) healthcare, trainee medical officers (TMOs) will play a crucial role in the development and use of artificial intelligence (AI) for clinical care, ongoing medical education and research. As 'digital natives', particularly those with technical expertise in AI, TMOs should also be leaders in informing the safe uptake and governance of AI within ANZ healthcare as they have a practical understanding of its associated risks and benefits. However, this is only possible if a culture of broad collaboration is instilled while the use of AI in ANZ is still in its initial phase.